Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADMA logo ADMA
Upturn stock ratingUpturn stock rating
ADMA logo

ADMA Biologics Inc (ADMA)

Upturn stock ratingUpturn stock rating
$17.26
Last Close (24-hour delay)
Today's Top Performer Top performer
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/29/2025: ADMA (5-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $29.06

1 Year Target Price $29.06

Analysts Price Target For last 52 week
$29.06 Target price
52w Low $13.5
Current$17.26
52w High $25.67

Analysis of Past Performance

Type Stock
Historic Profit 144.75%
Avg. Invested days 46
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/29/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.12B USD
Price to earnings Ratio 20.31
1Y Target Price 29.06
Price to earnings Ratio 20.31
1Y Target Price 29.06
Volume (30-day avg) 3
Beta 0.38
52 Weeks Range 13.50 - 25.67
Updated Date 08/29/2025
52 Weeks Range 13.50 - 25.67
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.85

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When -
Estimate 0.15
Actual 0.14

Profitability

Profit Margin 44.06%
Operating Margin (TTM) 35.09%

Management Effectiveness

Return on Assets (TTM) 20.81%
Return on Equity (TTM) 71.23%

Valuation

Trailing PE 20.31
Forward PE 28.99
Enterprise Value 4140941896
Price to Sales(TTM) 8.69
Enterprise Value 4140941896
Price to Sales(TTM) 8.69
Enterprise Value to Revenue 8.73
Enterprise Value to EBITDA 25.39
Shares Outstanding 238631008
Shares Floating 233862877
Shares Outstanding 238631008
Shares Floating 233862877
Percent Insiders 2.57
Percent Institutions 90.71

ai summary icon Upturn AI SWOT

ADMA Biologics Inc

stock logo

Company Overview

overview logo History and Background

ADMA Biologics, Inc. was founded in 2004. It's a biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases.

business area logo Core Business Areas

  • Plasma Collection: ADMA operates its own FDA-approved plasma collection centers to source raw material for its products.
  • Manufacturing: ADMA manufactures plasma-derived therapies, including intravenous immune globulin (IVIG) products.
  • Commercialization: ADMA commercializes and distributes its products to hospitals, pharmacies, and other healthcare providers.

leadership logo Leadership and Structure

ADMA is led by a management team with experience in the biopharmaceutical industry. The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • BIVIGAMu00ae: Intravenous Immune Globulin (IVIG) indicated for the treatment of primary humoral immunodeficiency (PI). Competitors include Grifols (GRFS), CSL Behring, Takeda (TAK), and Kedrion Biopharma. BIVIGAM revenue for 2023 was $135.1 million. Market share data specifically for BIVIGAM is difficult to ascertain precisely due to the broader IVIG market.
  • ASCENIVu2122: Intravenous Immune Globulin (IVIG) indicated for the treatment of primary humoral immunodeficiency (PI). Competitors include Grifols (GRFS), CSL Behring, Takeda (TAK), and Kedrion Biopharma. ASCENIV revenue for 2023 was $45.8 million. Market share data specifically for ASCENIV is difficult to ascertain precisely due to the broader IVIG market.
  • NABI-HBu00ae: Hepatitis B Immune Globulin (Human) for post-exposure prophylaxis. Competitors include Grifols (GRFS). Market share data specifically for NABI-HB is not readily available.

Market Dynamics

industry overview logo Industry Overview

The plasma-derived therapies market is growing due to increasing prevalence of immune deficiencies and infectious diseases. High demand and limited supply characterize the market.

Positioning

ADMA is a smaller player compared to industry giants but focuses on niche markets and vertically integrated operations (plasma collection).

Total Addressable Market (TAM)

The global immunoglobulin market is projected to reach USD 16.6 billion by 2029. ADMA is well-positioned to capture a portion of this TAM with its specialized IVIG products and control over plasma supply.

Upturn SWOT Analysis

Strengths

  • Vertically integrated operations (plasma collection)
  • Specialized IVIG products
  • FDA-approved manufacturing facilities
  • Focus on niche markets

Weaknesses

  • Smaller scale compared to larger competitors
  • Reliance on plasma supply
  • Limited product portfolio
  • High debt levels

Opportunities

  • Expanding plasma collection network
  • Developing new plasma-derived therapies
  • Acquiring complementary businesses
  • Increasing market share in niche areas

Threats

  • Competition from larger players
  • Fluctuations in plasma supply
  • Regulatory changes
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • GRFS
  • CSL
  • TAK

Competitive Landscape

ADMA is a smaller player competing with established giants. Its vertical integration and specialized products provide a competitive edge in niche markets.

Major Acquisitions

Plasma Centers

  • Year: 2022
  • Acquisition Price (USD millions): 32.5
  • Strategic Rationale: To increase plasma supply and reduce reliance on third-party suppliers.

Growth Trajectory and Initiatives

Historical Growth: ADMA has experienced significant revenue growth in recent years, driven by increased sales of its IVIG products.

Future Projections: Analysts expect continued revenue growth as ADMA expands its plasma collection network and introduces new products. Profitability is expected in the near future.

Recent Initiatives: Expansion of plasma collection centers, strategic acquisitions, and investment in R&D are recent initiatives.

Summary

ADMA Biologics shows potential with its growing revenue and strategic focus on plasma-derived therapies, particularly IVIG. While losses persist, improving gross margins and plasma collection expansion are positives. However, ADMA needs to address its debt and navigate competition to achieve sustainable profitability. Long term strategic goals need to be put in place.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Presentations
  • Analyst Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary based on source. Financial data is based on publicly available information and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ADMA Biologics Inc

Exchange NASDAQ
Headquaters Ramsey, NJ, United States
IPO Launch date 2013-10-17
Co-Founder, President, CEO & Director Mr. Adam S. Grossman
Sector Healthcare
Industry Biotechnology
Full time employees 685
Full time employees 685

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.